India’s 1st intranasal Covid vaccine launched on 26th Jan

The CMD of a well-known company known as Bharat Biotech has already declared that it will introduce the much-awaited intranasal Covid vaccine on the Republic Day of India (26th January this year). Earlier, this month, the CDSCO (Central Drugs Standard Control Organisation) provided its approval for this particular vaccination which happens to be the first of this type in this country.

The CMD, whose name happens to be Krishna Ella, announced that Bharat Biotech has been able to receive endorsement for launching the vaccination officially on 26th January. She confirmed this when she took part in a session that signified the India International Science Festival’s eighth edition commencing at the MANIT (Maulana Azad National Institute of Technology). Earlier, this company declared that the cost of the vaccine will be Rs 325 for each shot when the government authorities will administer it. On the other hand, the price will be Rs 800 for each shot when individuals will receive the vaccine from private centres.

Some more information that will be helpful to you

It will be a good idea to take this intranasal vaccine after a period of six months following the second Covid vaccine dosage.

According to the creators of this vaccine, it is possible to administer the medicine through the nose because of the nasal mucosa’s organized immune system. It is possible for the ChAd-SARS-CoV-2-S intra-nasal immunization to create a sort of immune response at the nose through which the virus can enter the human body. In this way, it will help to protect us from the ailment as well as transmission.

The price of nasal vaccination is affordable in the low-income countries

Dr. Krishna Ella declared that they have developed the iNCOVACC as well as the COVAXIN which happens to be a couple of vaccinations from various platforms along with various types of delivery systems. In this way, they have been able to attain the objectives that they had set for themselves during this pandemic situation. It is a fact that the intranasal delivery platform will provide us with the ability for scaling up, painless and easy immunization, as well as the ability to develop rapid products during this time of emergency situation.

iNCOVACC will help the variant-specific vaccines to develop quite rapidly and there will also be simple nasal delivery enabling the safeguard of mass immunization from different variants of concern that are coming up. Furthermore, apart from helping to combat Covid, this vaccination will likewise be beneficial for safeguarding against different types of infections and respiratory viruses.

This intranasal vaccine was developed in India in collaboration with Washington University, St Louis. The main purpose for developing this kind of nasal delivery system is that individuals in low-income and middle-income countries will be able to purchase it.